Ward, Laura M; Aitchison, Ross T; Hill, Gemma; Imrie, Jayne; Simmers, Anita; Morison, Gordon; Mansfield, David ; Kennedy, Graeme J; Shahani, Uma

Published in:
International Journal of Ophthalmology and Vision Research

Publication date:
2018

Document Version
Publisher's PDF, also known as Version of record

Link to publication in ResearchOnline@GCU

Citation for published version (APA):
Effects of Glaucoma and Snoring on Cerebral Oxygenation in the Visual Cortex: a Study Using functional Near Infrared Spectroscopy (fNIRS) -

Laura M Ward¹, Ross T Aitchison¹, Gemma Hill¹, Jayne Imrie¹, Anita J Simmers¹, Gordon Morrison¹, David Mansfield², Graeme J Kennedy¹ and Uma Shahani¹*

¹Departments of Vision Sciences, & Engineering Glasgow Caledonian University, 70 Cowcaddens Road, Glasgow, G4 0BA, United Kingdom
²Inverclyde Royal Hospital, NHS Greater Glasgow & Clyde, Larkfield Road, Greenock, PA16 0XN, United Kingdom

*Address for Correspondence: Uma Shahani, Departments of Vision Sciences and Engineering Glasgow Caledonian University, 70 Cowcaddens Road, Glasgow, G4 0BA, United Kingdom, Tel: +141- 331 -3695; ORCID: orcid.org/0000-0003-2597-9334;
E-mail: U.Shahani@gcu.ac.uk/uma.shahani@gmail.com

Submitted: 16 October 2018; Approved: 23 October 2018; Published: 26 October 2018


Copyright: © 2018 Ward LM, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Glaucoma is the leading cause of irreversible blindness worldwide [1], and affects approximately 2% of the UK population over 40 [2]. It is characterised by the eventual development of optic neuropathy. This is expressed as progressive Optic Nerve Head (ONH) damage with associated visual field loss. The exact pathophysiology of glaucoma is not yet fully understood, and although there are many established risk factors, the specific vascular dysregulation associated with glaucoma is not clear. Moore et al. [3] propose that the impairment of ocular blood flow could result in retinal ganglion cell death and changes in the ONH: both crucial elements in the pathophysiology of all glaucoma subtypes. It has been proposed that vascular dysregulation in the ONH may be due to vasospasm (abnormal vascular responsiveness [4]), independent of the effects of age [5]. This in turn, makes the eye more sensitive to fluctuations in Intracocular Pressure (IOP) and systemic blood pressure [6,7]. It is generally assumed that any vascular dysregulation in the ONH is localised to the blood vessels of the disc; however, there is a growing body of research suggesting deficits continue further up the visual pathway [8-14]. Evidence from healthy adults supports this: an artificial increase in IOP has been shown to result in decreased Visual Evoked Potential (VEP) amplitude [15]. It is increasingly recognised that there are a number of systemic risk factors associated with glaucoma, that include hypertension [8,16], other vascular risk factors [16], ocular perfusion pressure [17], migraine [18] & diabetes [19]. Given the above literature, it is not surprising that there is an increasing body of evidence linking glaucoma to Obstructive Sleep Apnoea (OSA).

Sleep related breathing disorders have been widely recognised as being on a continuum of pathophysiological cardiovascular and respiratory responses, all of which may have important acute and chronic health implications [20]. Within this spectrum is OSA, which is characterised as repeated interruptions of breathing during sleep, caused by the collapse of the upper airway [21]. OSA has significant health consequences including chronic sleep deprivation [22], cognitive decline [23-26], migraine [27], and cardiorespiratory dysfunction with consequences such as hypertension [28,29], heart failure or disease [25,30,31] and stroke [30,32-34]. Yet, OSA is often under-diagnosed as it requires a full polysomnographic evaluation which is an overnight diagnostic tool in sleep medicine that incorporates a battery of tests [22]. Apnoeic episodes can cause fluctuations in cerebral blood flow both in wakefulness and in sleep [35]. Many habitual snorers may have undiagnosed OSA [36], yet research shows snoring has similar implications on general health and cerebral haemodynamics as OSA [21,37-39]. Although there is evidence that suggests that snoring influences blood pressure through obesity, OSA and nocturnal hypoxia [40], there is an overwhelming body of literature that concludes that there is an increased risk of hypertension in snorers that is independent of age, weight or other lifestyle factors [41-44]. Snoring and nocturnal hypoxia are related to a wide number of ophthalmic complications most likely with a multifactorial origin [19]. While we aim to investigate the potential link between these two conditions, this relationship is particularly difficult to study as it may be confounded by other underlying risk factors such as hypertension and diabetes [45], that are systemic in nature.

There is mixed evidence regarding the relationship between glaucoma and OSA, both conditions with haemodynamic consequences. Whilst some studies have shown an increased prevalence of OSA in glaucoma patients [46-54], others have failed to support this finding [55-59]. In early 2015 two meta-analyses were published both reporting a statistically significant relationship with OSA as having an association with an increased prevalence of glaucoma. The first study included 12 research papers and reported the odds ratio of 1.65 [60] to be the measure of association between glaucoma and OSA. Therefore, the odds of glaucoma and OSA occurring together were higher than in the normal population. The second meta-analysis paper used a more systematic approach, categorising literature into either case-control or cross-sectional studies - including 9 of the original 12 studies used by Wu and Liu [60] and reported an odds ratio of 1.96 and 1.41 respectively by pooling data from 2.3 million participants [61]. Despite the difficulty of the many studies’ varying methodologies, inclusion criteria, types of patients (both glaucoma and OSA), there is undoubtedly strong evidence to suggest that a relationship exists between these two conditions.

There are two theories attempting to explain this association: a mechanical theory and a vascular theory. The mechanical theory centres on the link between pressures and glaucoma: OSA causes sleep disturbances and changes in sympathetic tone [44], metabolic dysfunction and systemic inflammation [29], which subsequently leads to ONH damage and potentially glaucoma [48,61,62]. Alternatively,
the vascular theory postulates that during apnoeic events (temporary suspension of breathing) in OSA, the decrease in oxygen levels leads to progressive asphyxia exhausting the cerebrovascular reserve [38]. This in turn, results in damage to the ONH [46], retinal nerve fibre layer [17], and may have the potential to cause changes in brain activation and morphology [63]. The current study contributes to the vascular theory as well investigates the apparent link between glaucoma and snoring by examining the Haemodynamic Response (HDR) associated with each.

Functional Near Infrared Spectroscopy (fNIRS) can provide a measure of cortical processing of the associated HDR to neuronal firing, providing a non-invasive measure of imaging cortical processing. fNIRS is an optical neuroimaging technique that uses near infrared light to measure changes of blood oxygenation concentrations in the cortex, recording both oxy- ([HbO]) and deoxy-Haemoglobin ([HbR]) concentrations [64]. Previous research has used fNIRS to successfully characterise the HDR to visual, auditory and physiological stimuli, proving it to be a reliable neuroimaging technique [65-76]. This evidence has proven fNIRS to be a valuable neuroimaging tool for both normal and clinical populations to assess cerebral haemodynamics.

To our knowledge, this is the first study to use fNIRS to explore the haemodynamic relationship between glaucoma and snoring in terms of a task-related visual HDR. According to the vascular theory of OSA, apnoea reduces blood oxygenation, which in turn causes damage to the ONH. To test the hypothesis that apnoea also has detrimental effects on the primary Visual Cortex (V1), we completed a pilot study using fNIRS to measure the HDR in response to a reversing checkerboard stimulus in habitual snorers and in glaucoma patients.

MATERIALS & METHODS

Patients

We recruited participants with glaucoma or habitual snorers, with individual approximate age-matched controls. There were 8 glaucoma patients (range 56 - 78 years old, 3 females), 6 snorers (range 26 - 61 years old, 3 females) and 10 control participants (range 21 - 74 years old, 8 females). All participants were recruited from the Glasgow Caledonian University (GCU) Vision Centre patient database or from the GCU staff list. Participants who reported that they snored, and experienced frequent episodes of apnoea, were included in the snorers group and were considered potential OSA sufferers. Neither control nor glaucoma group participants reported such severe snoring and/or sleep related difficulties. None of the participants were current smokers, a number were on hypertensive medication and had other medical history; these details can be seen in table 1. A full medical history was taken and all participants completed a short general health questionnaire before beginning the tasks. This included a short health related Activities of Daily Living (ADL) questionnaire designed to assess how much illness interferes with patients’ daily living [77]. Resting blood pressure and heart rate were measured using a non-invasive blood pressure cuff applied to the left arm. This study was approved by the ethics Committee of Glasgow Caledonian University. Informed written consent was obtained from all participants prior to testing in accordance with the Declaration of Helsinki (Table 1).

Procedure

Visual assessment: All participants had measurements of visual acuity taken prior to testing. Glaucoma patients were selected from the GCU Eye Clinic database. All had undergone a recent eye examination within the GCU Eye Clinic and were under the care of an ophthalmologist for monitoring of their glaucoma. Measures of IOP, cup-to-disc ratio, and visual fields (Humphrey Visual Field Analyzer, Central 24-2 SITA FAST) were taken from the clinical record of their most recent eye examination (Table 1).

fNIRS protocol: A Frequency-Domain Multi-Distance (FD-MD) fNIRS system was used (OxiplexTS™), allowing us to determine absolute quantities of cerebral haemoglobin chromophore concentration ([chromophore]). This instrumentation uses 2 wavelengths of light (690 nm, 830 nm), is frequency modulated (110 MHz) and uses near infrared light photon absorption, scattering and phase data to calculate change in [HbO] and [HbR] to. To assess the HDR of V1 we recorded over O1 and O2 according to the EEG 10-20 International System of Electrode Placement [78]. A standard ISCEV visual stimulus was used [68,79] : full-field reversing checkerboard (100% contrast, 7.5 Hz temporal frequency, 30 minutes of arc check size). These parameters ensured all participants could comfortably perceive the stimulus and reliable data would be collected. Participants were seated in an upright position 1 meter away and were asked to fixate on a central blue dot displayed throughout the task. A pre-task baseline recording was collected in response to a grey screen of equal mean luminance to the checkerboard for 2 minutes. The reversing checkerboard or grey screen was intermittently displayed for 30 seconds each for 10 cycles. This instrumentation and protocol has been described in detail elsewhere [68,80,81]. Figure 1 shows the experimental set up.

Data analysis: Data were pre-processed in MATLAB as previously published68. Briefly, all data were normalised with respect to the pre-stimulus baseline and a moving average low-pass filter was applied. An average HDR to the checkerboard was calculated by averaging across all data responses to the experimental cycles. Lastly, a grand average was taken of the last 15 seconds of data per phase, representing the greatest stable change of the HDR [68,69,72,73,82-85].

RESULTS

Visual Stimulation

As no statistically significant differences were found between hemispheres (O1,O2) these data were averaged to create an overall V1 response. Additionally, to investigate potential differences at baseline, a 2-way ANOVA was performed on the pre-experimental data entering cerebral [chromophore] ([HbO], [HbR]) as a within-subject factor and group as a between-subject factor. This failed to show any group differences (F1,21 = 1.69, p > 0.05), indicating our samples were comparable before beginning the visual task and resting-state HDR were similar amongst participants. There was a clear response to the visual stimulation in all three groups. A two x 2 repeated measures ANOVA was performed with stimulation (checkerboard on, off) and cerebral [chromophore] ([HbO], [HbR]) as within-subject factors and groups entered as between-subject factors. There was a main effect of visual stimulation (F1.48 = 20.9, p < 0.001, η² = 0.52), oxygenation (F1.48 = 7.47, p < 0.05, η² = 0.28), and an interaction between the two (F1.48 = 58.2, p < 0.001, η² = 0.75). When examining the overall HDR for each group this can be seen as a characteristic increase in [HbO] and decrease in [HbR] during the checkerboard stimulation compared to the baseline grey screen (Figure 2, A-C). Group differences were apparent with 3 group interactions all with large effect sizes: group and...
stimulation ($F_{1,19} = 5.63, \ p < 0.05, \ \eta^2 = 0.37$), group and oxygenation ($F_{1,19} = 11.57, \ p < 0.001, \ \eta^2 = 0.55$), and group, stimulation and oxygenation ($F_{2,19} = 3.69, \ p < 0.05, \ \eta^2 = 0.28$). Post-hoc independent samples t-tests were used to compare the group differences with corrected confidence intervals of 99.99%. During the ‘on’ phase of visual stimulation, controls had a greater change of [HbO] compared to snorers (mean difference = 0.393, $t_{12} = 3.45, \ p < 0.01, \ d_s = 1.92$), and glaucoma patients (mean difference = 0.350, $t_{10} = 3.93, \ p < 0.01, \ d_s = 1.91$). These results represent the greatest stable change in the HDR in response to the reversing checkerboard and demonstrate compelling differences between the groups with large effect sizes. This can be seen in the overall HDR in figure 2 (D) wherein both glaucoma (dashed red line) and snorer groups were statistically comparable in terms of their HDR in V1 in both ‘on’ and ‘off’ phases for both [HbO] and [HbR] ($p > 0.05$). Please note these statistical results remained when the two glaucoma patients with concomitant AMD were removed from the analyses. In terms of [HbR] all groups were comparable during both phases of visual stimulation ($p > 0.05$) (Figure 2).

**Glaucoma correlations**

To investigate the relationship between optical measures of visual function and cerebral oxygenation, we computed a correlational analysis within the glaucoma group. Bias corrected and accelerated bootstrap confidence intervals using 5000 resamples and a 95% confidence interval [86] were used. All outcome measures were entered (fNIRS data, visual acuity, visual fields, blood pressure, heart rate, ADL and age). It has been suggested that the pattern standard deviation of the visual fields may underestimate the extent

<table>
<thead>
<tr>
<th>Group</th>
<th>Subject</th>
<th>Medical notes</th>
<th>Age</th>
<th>Sex</th>
<th>VA</th>
<th>BP</th>
<th>HR</th>
<th>ADL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>1</td>
<td>21 F</td>
<td>0.0</td>
<td>0</td>
<td>117</td>
<td>74</td>
<td>98</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>26 F</td>
<td>-0.2</td>
<td>-0.2</td>
<td>131</td>
<td>74</td>
<td>63</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>28 F</td>
<td>-0.2</td>
<td>-0.2</td>
<td>122</td>
<td>68</td>
<td>50</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>42 F</td>
<td>-0.1</td>
<td>-0.1</td>
<td>141</td>
<td>91</td>
<td>70</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>56 F</td>
<td>-0.1</td>
<td>-0.1</td>
<td>118</td>
<td>64</td>
<td>65</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>58 M</td>
<td>0.0</td>
<td>0.0</td>
<td>131</td>
<td>90</td>
<td>72</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>68 F</td>
<td>0.0</td>
<td>0.0</td>
<td>124</td>
<td>87</td>
<td>72</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>Hypertensive medication</td>
<td>74 M</td>
<td>-0.1</td>
<td>0.3</td>
<td>133</td>
<td>84</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>Subclinical cataracts, hypertensive medication</td>
<td>77 F</td>
<td>0.0</td>
<td>-0.1</td>
<td>156</td>
<td>105</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>Cataract removal previously</td>
<td>78 F</td>
<td>0.0</td>
<td>0.0</td>
<td>138</td>
<td>80</td>
<td>90</td>
</tr>
<tr>
<td>Snorer</td>
<td>11</td>
<td>26 F</td>
<td>0.0</td>
<td>0.0</td>
<td>132</td>
<td>91</td>
<td>105</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>CPAP</td>
<td>47 F</td>
<td>0.0</td>
<td>-0.1</td>
<td>124</td>
<td>86</td>
<td>71</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>57 M</td>
<td>0.0</td>
<td>0.0</td>
<td>157</td>
<td>107</td>
<td>54</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>Hypertensive medication</td>
<td>58 F</td>
<td>0.0</td>
<td>0.0</td>
<td>136</td>
<td>82</td>
<td>72</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>Type 1 Diabetes insulin injections, hypertensive medication</td>
<td>58 M</td>
<td>0.0</td>
<td>0.0</td>
<td>118</td>
<td>84</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>61 M</td>
<td>-0.1</td>
<td>-0.1</td>
<td>128</td>
<td>79</td>
<td>87</td>
<td>0.00</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>17</td>
<td>PDS/ PG, Xalatan treatment</td>
<td>56 M</td>
<td>0.0</td>
<td>0.0</td>
<td>169</td>
<td>79</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>POAG, ARMD, Bimatoprost &amp; brinzolamine/ timolol combination eye drops</td>
<td>69 M</td>
<td>0.0</td>
<td>0.0</td>
<td>137</td>
<td>82</td>
<td>73</td>
</tr>
<tr>
<td></td>
<td>19</td>
<td>POAG, Bimatoprost/ timolol combination eye drops</td>
<td>70 M</td>
<td>0.0</td>
<td>-0.1</td>
<td>100</td>
<td>71</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>Suspected glaucoma, hypertensive medication</td>
<td>72 M</td>
<td>0.0</td>
<td>0.2</td>
<td>134</td>
<td>82</td>
<td>69</td>
</tr>
<tr>
<td></td>
<td>21</td>
<td>NTG, hypertensive medication, Aspot eye drops</td>
<td>73 F</td>
<td>0.6</td>
<td>1</td>
<td>136</td>
<td>82</td>
<td>71</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>Longstanding NAG treated with trabeculectomies, ARMD, hypertensive medication</td>
<td>77 F</td>
<td>0.3</td>
<td>0.2</td>
<td>170</td>
<td>87</td>
<td>113</td>
</tr>
<tr>
<td></td>
<td>23</td>
<td>Longstanding NAG treated with trabeculectomies, hypertensive medication</td>
<td>78 M</td>
<td>0.2</td>
<td>balance</td>
<td>164</td>
<td>89</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>POAG, hypertensive medication, Timolol &amp; latanoprost eye drops</td>
<td>79 F</td>
<td>0.2</td>
<td>0.2</td>
<td>152</td>
<td>84</td>
<td>63</td>
</tr>
</tbody>
</table>

Table 1: Individual participant details, group assignment, medical notes, age, sex, Visual Acuity (VA) for left and right eyes, Blood Pressure (BP), Heart Rate (HR) and Activities of Daily Living (ADL) score.
of glaucomatous damage [87]. We therefore used the mean defect as a global index. The IOPs were excluded from the statistical analysis because of normal daily fluctuations of IOP and also because several of the glaucoma patients used eye drops to lower their IOP (Table 1). There was a significant relationship between V1 [HbO] and the left eye visual field ($r = -0.98$, $p < 0.001$, CI = [-0.49 -1]). Also, the right visual field correlated significantly with patients’ reported ADL ($r = -0.82$, $p < 0.05$, CI = [-0.02 -0.99]). Note that these statistics remained when glaucoma patients with only one glaucomatous eye were removed. These correlations imply that those patients with worse mean defects on their visual fields had higher ADL scores, and smaller changes in [HbO] in response to the checkerboard stimulation, regardless of the inclusion/ exclusion of those glaucoma patients with concomitant AMD.

**DISCUSSION**

To clarify the potential vascular relationship between glaucoma and OSA, we used fNIRS to quantify changes in [HbO] and [HbR] during a visual task. As this was a pilot study with inherent constraints, we recruited all subtypes of glaucoma patients and habitual snorers, but recruitment to these groups was mutually exclusive. Although all participants produced a reliable V1 HDR to the reversing checkerboard, with a distinctive increase of [HbO] and decrease of [HbR] during visual stimulation, there were statistically significant group differences with strong effect sizes. In response to visual stimulation, snorers had the smallest change in [HbO], followed by glaucoma patients who also showed an attenuated response in comparison to healthy participants (Figure 1D). These results show that 28% of variance in the HDR elicited by visual stimulation, is attributable to group characteristics ($p < 0.05$, $\eta^2 = 0.28$), therefore the magnitude of these findings is considerable. Here, we report the novel finding that in response to visual stimulation, both glaucoma patients and habitual snorers present with an attenuated [HbO] response in comparison to healthy participants. This finding relates specifically to the systemic influences of each of these syndromes. Our glaucoma patients did not snore, and our habitual snorers did not have any glaucoma. Therefore, these groups were mutually exclusive. Accordingly, these results support the vascular theory hypothesis that apnoea may affect not just the ONH but further up in the visual pathway such as the visual cortex. There is significant support for this evidence of neuronal degeneration in glaucoma extending beyond the retina. In the primate model of glaucoma, neuronal loss was reported by Yucel et al. [88], in both M and P pathways of the Lateral Geniculate Nucleus (LGN) of the fellow eye, as well as the glaucomatous eye. This degeneration has been confirmed in humans using functional Magnetic Resonance Imaging (fMRI): not only do glaucoma patients present with LGN atrophy in comparison with healthy controls [11], but the degeneration correlates with their clinical severity as measured by visual fields [89]. High tension and primary open-angle glaucoma patients show a decrease in V1 cortical activation as measured by fMRI [90-94], whereas normal tension glaucoma patients do not [90]. Diffusion Tensor Imaging (DTI) has also highlighted the involvement of the entire visual pathway, with clinical glaucoma stages correlating with DTI parameters thought to reflect axonal damage to the optic radiations [95]. Lastly, a clinicopathological case of a male glaucoma patient supported this with visual pathway damage from the LGN to V1 correlating with visual field loss [10]. Regarding OSA, previous reports have shown no significant differences in V1 grey matter volume between patients and controls [63]; ours is the first study to report a reduction in functional activation in habitual snorers in comparison to health controls (Figure 1). These results complement previous literature in which fNIRS was used to record the HDR from frontal cortex of sleeping OSA patients, and where it was demonstrated that there was a reduced cortical response [67,96-99].

We also show that ADL, a self-report measure of the patients’ perspective of how much their illness interferes with their social/role activities, significantly correlated with visual field mean defect. This short but effective questionnaire has provided results similar to more extensive quality of life assessments for glaucoma patients [100,101]. Visual fields also correlated with [HbO] responses during visual stimulation. The results illustrated that those patients with worse fields presented with an attenuated [HbO] response to checkerboard stimulation, and felt subjectively that their vision was having a negative impact on their overall daily life. These findings directly support previous neuroimaging evidence of a strong correlation between reduced resting cerebral blood flow and loss of visual...
function [90-94]. The modified HDR in V1 in both resting state and functional tasks, indicates that the vascular dysregulation linked to glaucoma, has effects further up the visual pathway beyond retinal ganglion cells as previously discussed. We propose that visual field defects have a direct impact on V1 functioning, though this may be due to a number of reasons within the visual pathway such as retinal ganglion cell loss or vascular dysregulation of V1.

An interesting discussion point is Subject 17 who was referred to an ophthalmologist from the GCU Eye Clinic for suspected glaucoma and was tested prior to his ophthalmology appointment. He was subsequently assessed and diagnosed with narrow anterior chamber angles and asymmetric optic disc cupping, but with no evidence of glaucoma. Yet, compared to the other glaucoma patients, he had a similar cup-to-disc ration, IOP and visual fields (Table 1). When examining the HDR in V1, this subject also displayed a median response within the glaucoma group. This highlights the variability of the glaucoma syndrome along with the current diagnostic and monitoring techniques for disease progression. Here we propose fNIRS to be an objective tool that could assist in glaucoma diagnosis and monitoring. FDMD-fNIRS is portable, cost effective and could easily be used in an eye clinic or hospital setting to aid clinicians. In this way, fNIRS could be used to discriminate potential glaucoma sufferers based on their HDR. Additionally, during glaucoma screening and diagnosis, patients’ potential risk for developing OSA could be highlighted by NIRS for referral to a sleep clinic for further testing. Clearly future work would need to provide normative NIRS data for glaucoma patients who are not yet undergoing treatment. In this way we could ascertain whether this attenuated V1 HDR can be accounted for by reduced neuronal input to the visual cortex due to glaucomatous defects in the visual field.

Various limitations to this study warrant discussion. Firstly, our small sample size for each experimental group makes it difficult to reach any generalised conclusions to the wider populations. This weakness is not novel as it is clear that both of these syndromes do not have pathognomonic signs, with numerous overlapping risk factors and patients presenting with varied characteristics. However, as this was an exploratory study, with few exclusion criteria, we aimed to provide a representative sample of data on the haemodynamic consequences of both conditions. Future research would ideally involve diagnosed OSA patients using overnight polysomnography and NIRS, in which more generalised conclusions may be made. Here we present characteristic findings relating habitual snorers to glaucoma patients and healthy controls. Our data show for the first time that snorer’s small sample size for each experimental group makes it difficult to reach a marker of poor health, and not necessarily an independent risk factor investigating glaucoma and OSA, and suggest OSA may merely be a highlight the necessity of careful control of systemic confounds when of research is to disentangle the numerous pathophysiological links in assessing the HDR of patient populations. The difficulty in this field to conclude, the HDR recorded from V1 to visual stimulation is attenuated regardless of the pathophysiology of our snorers and glaucoma patients. Our results show the potential of NIRS to assess changes in the HDR in identifying potential ‘at risk’ glaucoma patients. Likewise for habitual snorers before they develop OSA. Further data on untreated glaucoma patients is crucial, and it may be that the V1 HDRs indicate early glaucomatous changes. This, in conjunction with existing diagnostic techniques and fNIRS measures of V1, would be advantageous in the diagnosis of glaucoma. We have presented novel results that show the potential of fNIRS as a method that provides an objective measure of absolute cerebral oxygenation in clinical populations.

ACKNOWLEDGEMENTS

Our deepest gratitude is extended to all the participants and patients that volunteered their time to take part in this study.

AUTHOR CONTRIBUTION STATEMENT

LW, RA, GH, JL, DM, GK and US made a substantial contribution to the concept and design, acquisition of data or analysis and interpretation of data. LW and US drafted the article or revised it critically for important intellectual content.

REFERENCES


29. Lattimore J DL, Celermajer DS, Wilcox I. Obstructive sleep apnea and
28. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Prospective study of the
24. Ayalon L, Peterson S. Functional central nervous system imaging in the
23. Beebe DW, Gozal D. Obstructive sleep apnea and the prefrontal cortex:
19. Attarian H, Viola-Saltzman M, Jay WM. Ophthalmic and neuro-ophthalmic
20. Wenner JB, Cheema R, Ayas NT. Clinical manifestations and consequences
15. Kremmer S, Tolksdorf Kremmer A, Stodtmeister R. Simultaneous registration
16. Leske MC, Heijl A, Bengtsson B, Dong L, Yang Z. Predictors of
27. Faridi O, Park SC, Liebmann JM, Ritch R. Glaucoma and obstructive sleep
46. Tsang CS, Chong SL, Ho CK, Li MF. Moderate to severe obstructive sleep apnea syndrome is associated with a higher incidence of visual field defect. Eye. 2006; 20: 38-42. https://goo.gl/7GiGiw


